Media headlines about Steadymed (NASDAQ:STDY) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Steadymed earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.2524721337635 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of STDY traded up $0.02 during mid-day trading on Friday, hitting $4.73. 40,515 shares of the company traded hands, compared to its average volume of 120,654. Steadymed has a one year low of $2.60 and a one year high of $6.45. The stock has a market capitalization of $125.14 million, a P/E ratio of -10.99 and a beta of 0.47.

Steadymed (NASDAQ:STDY) last released its quarterly earnings results on Tuesday, May 15th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.18). Steadymed had a negative net margin of 2,177.00% and a negative return on equity of 68.96%. sell-side analysts anticipate that Steadymed will post -0.76 EPS for the current fiscal year.

STDY has been the subject of several recent analyst reports. ValuEngine raised shares of Steadymed from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. JMP Securities reissued a “market perform” rating on shares of Steadymed in a research note on Tuesday, May 1st.

In related news, CFO David W. Nassif sold 10,001 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $4.50, for a total transaction of $45,004.50. Following the sale, the chief financial officer now directly owns 34,314 shares in the company, valued at $154,413. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David W. Nassif sold 12,157 shares of the firm’s stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $4.50, for a total transaction of $54,706.50. Following the sale, the chief financial officer now owns 22,157 shares in the company, valued at $99,706.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,724 shares of company stock worth $309,258. 38.63% of the stock is currently owned by company insiders.

About Steadymed

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Insider Buying and Selling by Quarter for Steadymed (NASDAQ:STDY)

Receive News & Ratings for Steadymed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steadymed and related companies with MarketBeat.com's FREE daily email newsletter.